Apaxen SA, a privately-held biotechnology company, developing novel next generation NLRP3
inflammasome inhibitor drugs for treatment of chronic inflammatory and
auto-immune diseases, announced today that it has appointed Graham K. Dixon,
PhD as Chairman of its Board of Directors and that it is preparing for clinical
testing of its lead product MFC-1040.
The
appointment of Dr Graham Dixon as Chairman is an important step in the
transformation of Apaxen from a pre-clinical to a clinical stage company.
During his successful carreer in C-suite management positions at companies such
as Galapagos, Addex Therapeutics and Mithra Pharmaceutical, he was instrumental
to the regulatory approval of three pharmaceutical products, twelve proof of
concept studies and ten clinical stage licensing deals. He is an experienced
non-executive director and board chairman as well as an advisor to several venture
capital organisations and their portfolio companies.
In addition,
Apaxen expects to complete IND enabling pre-clinical testing of its lead NLRP3
inflammasome inhibitor MFC-1040 by end of 2022 and aims to raise series B
round financing by early 2023 to fund the clinical development plans of the
company.
Bart Wuurman, CEO of
Apaxen, stated:
“We
are very pleased to welcome Graham as Chairman of Apaxen’s Board of Directors
with his experience and extensive track record of leading biotechnology
companies through strategic periods of growth. He will be a great asset for the
company entering its phase of clinical development and we look forward to
working with him.“
Graham Dixon, newly
appointed Chairman of Apaxen, comments:
“I
am very excited to join the Apaxen team. With its novel approach to inhibiting
NLRP3 inflammasomes the Company is moving into the next stage of growth and we
will be looking for new high quality investors to support the company
financially. I look forward to guiding Apaxen during this exciting time in the
Company’s development and supporting the team to achieve our mission of helping
patients with severe inflammatory and autoimmune diseases.”
No comments:
Post a Comment